Predictable reimbursement is a primary operational determinant of biosimilar longevity in practices, frequently outweighing ...

A drug selected for the latest round of Medicare drug price negotiations stands to get dropped because a lower-cost ...

MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira® (adalimumab) priced at 95% below ...

Aprogen spikes on biosimilar progress as Korea weighs risks from capital cut Shares hit limit-up on biosimilar shortcut hopes ...

The global biosimilar contract manufacturing market size was valued at USD 9.22 billion in 2025 and is predicted to hit ...

Under the terms of a settlement and license agreement with Regeneron, Samsung Bioepis will be able to launch Opuviz in the ...

Biosimilar Ranluspec is used to treat neovascular (wet) age-related macular degeneration and other retinal vascular disorders ...

Although there is a paucity of data of switching among biosimilars of the same reference product, the few studies published support the safety and effectiveness of transitioning patients from one ...

The FDA approves biosimilar chemo infection risk treatment Filkri for cancer patients, expanding granulocyte colony-stimulating factor options.

Shilpa Biologicals has signed a licensing agreement with SteinCares to commercialize a biosimilar in the latter’s home region, Latin America.

Latin American specialty pharma company SteinCares has signed a licensing agreement with India’s Shilpa Biologicals to commercialize a biosimilar across Latin America, marking the Indian group’s first ...

Investing.com -- Lupin received approval from the European Commission for its biosimilar ranibizumab, the pharmaceutical ...